GSK makes FDA bid for first-line Arzerra use; Irish pharma jobs shrink by up to 20%; Russian pharma eyes Brazilian biosims market;

@FiercePharma:  ICYMI, most popular special report this weekend: Top 15 Drug Launch Superstars | Follow @FiercePharma

@EricPFierce: Novartis' Sandoz is the 2nd largest generics maker in the world. It targets biosimilars to stay there. More | Follow @EricPFierce

@CarlyHFierce: We now present: Top 10 generics makers by 2012 revenue. Special report | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) and Genmab asked the FDA to approve first-line use of their chronic lymphocytic leukemia drug Arzerra. Report

> The Irish pharma industry has lost up to 20% of its jobs over the past 3 to 5 years as patent-cliff losses hit local Big Pharma operations. Report

> Russia's Biocad is set to open a $40 million plant in Brazil to make three biosimilar drugs for sale in that market. Report

> Iroko Pharmaceuticals won the FDA nod for its pain drug Zorvolex (diclofenac), a non-steroidal anti-inflammatory, at dosages 20% lower than other available versions. Report

> Specialty drugmaker Meda closed its $135 million buyout of Acton Pharmaceuticals and its product Aerospan. Report

> Three dozen lawsuits alleging that Pfizer's ($PFE) Lipitor is unsafe were transferred to federal court; in responding to the suit, Pfizer said Lipitor's risks are outweighed by its benefits. Report

> Smaller Indian drugmakers such as Intas Pharmaceuticals, Macleods Pharma and Hetero Labs are tapping the U.S. market. Report

Medical Device News

@FierceMedDev: Cheney worried defibrillator was vulnerable to hacking from terrorists. Item | Follow @FierceMedDev

@MarkHFierce: Kona Medical, a 2013 Fierce 15 winner, drew in $10M in new funding to hit China with its renal denervation device. Release | Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: AstraZeneca teams with Taris to research bladder cancer delivery device. Story from FierceDrugDelivery | Follow @MichaelGFierce

> DoD ponies up $15M to develop Terumo's blood-cleaning tech. News

> Bard recalls vascular stent due to deployment malfunction risks. Story

> Medtronic launches clot-removal tech in U.S. Article

Biotech News

@FierceBiotech: ICYMI last week: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceBiotech

@JohnCFierce: Latest biotech IPO tally: 39 done, 15 in the queue--report updated with stock performance as of last Thursday. Feature | Follow @JohnCFierce

@DamianFierce: Quintiles is shuttering an early-phase Indian facility as regulatory hurdles make times tough. FierceCRO article | Follow @DamianFierce

@EmilyMFierce: FierceBiotech is looking for an associate editor. Details here | Follow @EmilyMFierce

> Iroko gets a thumbs-up from FDA on lower-dose NSAID. Item

> Novartis advances rival CDK 4/6 cancer drug to Pfizer's palbociclib. Article

> TetraLogic joins IPO rush with $103.5M offering to fuel cancer drug R&D. News

> Lilly's Lechleiter isn't budging from stand-alone $5B R&D strategy--yet. Story

> Actelion wins crucial FDA approval for next-gen lung disease drug Opsumit. News

CRO News

> WuXi is first in China with CLIA-OK genomics lab. Item

> Novella teams with Scioderm for 'breakthrough' drug. More

> DrugDev picks up CFS Clinical for trial software. Story

> Aenova snags Haupt to boost CMO presence. News

> Clinlogix buys German CRO with eye on Euro demand. Article

Biotech IT News

> Pfizer and Roche back protein shape change monitoring startup. Story

> Deloitte unveils another EHR-driven software tool. News

> Statisticians fret over misuse of data-crunching software. More

> Veeva stock soars following successful IPO. Article

> Roche to shutter 454, 6 years after buying NGS business. Story

And Finally... Brazilian animal-rights activists released 178 beagles used in pharma research as part of a raucous protest at the Instituto Royal lab in Sao Roque. Report

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.